Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Blood (2019) 134 (Supplement_1): 2031.

https://doi.org/10.1182/blood-2019-125646

Published: 2019

Journal Articles

Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies

Charlotte K. Brierley, MD, Francesca M Jones, MD, Katherine Hanlon, MD, Andrew Peniket, MD, Patrick Medd, MD PhD, Andrew Clark, MD, Anne Parker, MD, Sridhar Chaganti, MD PhD, Ram Malladi, MD PhD, Charles Craddock, MD PhD, Robert Danby, MD PhD, Vanderson Rocha, MD PhD

Blood (2016) 128 (22): 3500.

https://doi.org/10.1182/blood.V128.22.3500.3500

Published: 2016

Journal Articles

Significantly Lower Cryopreservation Volumes for PBSC Collections Using Spectra Optia® Version 5 Software Compared with the MNC Setting on COBE® Spectra, Particularly When Using Plerixafor for Mobilisation

Mhairi Copland, PhD, BSc, MRCP, FRCPath, Michael Alcorn, Ph.D., Daniela Patton, Ph.D., Allyson Doig, Ph.D., Elizabeth Farrell, Ph.D., Colette Currie, RGN, Joy E Sinclair, RGN, Anne Parker, MD, FRCP, FRCPath, BSc, Kenneth W Douglas, MBChB, BSc, FRCP, FRCPath

Blood (2010) 116 (21): 825.

https://doi.org/10.1182/blood.V116.21.825.825

Published: 2010

Journal Articles

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Adrian Bloor, MD, Gordon Cook, MD, Donald Milligan, MD, Anne Parker, MD, Charles Craddock, MD, Lynny Yung, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1661.

https://doi.org/10.1182/blood.V110.11.1661.1661

Published: 2007

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): Report of 11 Cases.

Juan-Manuel Sancho, MD, Anne Parker, MD, Guillermo Deben, MD, Simon Bolam, MD, Eugenio Gimenez, MD, Eva Sanchez-Garcia, MD, Jose-Luis Piñana, MD, Teresa Pascual, MD, Carmen Mateos, MD, Pascual Fernandez-Abellan, MD, Luis Palomera, MD, Josep-Maria Ribera, PhD

Blood (2006) 108 (11): 4545.

https://doi.org/10.1182/blood.V108.11.4545.4545

Published: 2006

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

Journal Articles

Psychosocial Screening for Bone Marrow Transplant Recipients.

Matt R. Wild, DClinPsy, Laura Meehan, RGN, Jane Laing, RGN, Anne Parker, MD

Blood (2004) 104 (11): 5025.

https://doi.org/10.1182/blood.V104.11.5025.5025

Published: 2004

NARROW

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies

Significantly Lower Cryopreservation Volumes for PBSC Collections Using Spectra Optia® Version 5 Software Compared with the MNC Setting on COBE® Spectra, Particularly When Using Plerixafor for Mobilisation

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): Report of 11 Cases.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Psychosocial Screening for Bone Marrow Transplant Recipients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only